Welcome to GTx, a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, bone loss, muscle wasting and other serious medical conditions.
Our recognized scientific expertise is in the discovery and development of novel, selective small molecules that target established hormone pathways. Click to learn more about our products in development.
GTx is transforming from a company focused on the discovery and development of drug candidates into one that will also commercialize our products. Click to learn more about the GTx management team.
GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting 
GTx Announces Ostarine(TM) (MK-2866) Clinical Trial Data to be Presented at ENDO 2009
GTx Announces Webcast of Corporate Presentation at Goldman Sachs 30th Annual Global Healthcare Conference